Advertisement
Organisation › Details
Argenx SE (Euronext + Nasdaq: ARGX)
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates. *
Start | 2019-03-28 renamed before | |
Predecessor | Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX) | |
Industry | therapeutic antibody | |
Industry 2 | SIMPLE Antibody™ discovery platform | |
Person | Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G) | |
Street | 5 Willemstraat | |
City | 4811 AH Breda | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | E: 501 to 1,000 (2022-03-01) |
Currency | USD | |
Annual sales | 539,418,000 (income, operating, consolidated (2021) 2021-12-31) | |
Profit | -408,265,000 (2021-12-31) | |
Cash | 2,336,728,000 (2021-12-31) | |
* Document for »About Section«: Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Argenx (Argen-X) (Group)
- [1] TVM Capital Life Science. (1/18/22). "Press Release: TVM Capital Life Science Promotes Dr. Sascha Berger and Dr. Alain Thibault to General Partner". Munich & Montréal....
- [2] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
- [3] Argen-X N.V. (Argenx). (12/3/18). "Press Release: Argenx Enters Exclusive Global Collaboration and License Agreement with Cilag GmbH International, an Affiliate of Janssen, for Cusatuzumab (ARGX-110)". Breda & Ghent....
- [4] Argen-X N.V. (Argenx). (11/1/18). "Press Release: Argenx Announces New Cusatuzumab (ARGX-110) AML Data in Abstracts Published in Connection with 60th American Society of Hematology Annual Meeting and Exposition". Breda & Ghent....
- [5] Argen-X N.V. (Argenx). (4/9/18). "Press Release: Argenx Appoints Keith Woods as Chief Operating Officer". Breda & Ghent....
- [6] Argen-X N.V. (Argenx). (4/12/17). "Press Release: Argenx Launches Phase II Study of ARGX-110 as a Monotherapy in Relapsed/Refractory CTCL Patients". Breda & Ghent....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top